Blue Dogs Lead Bipartisan Effort to Lower Prescription Drug Costs, Increase Transparency
The Blue Dog Coalition on Wednesday threw its support behind two bipartisan bills that aim to lower prescription drug costs and increase transparency in the drug pricing system.
The coalition is a House caucus of moderate and fiscally responsible Democrats. The bills they endorsed are the Payment Commission Act and the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act.
Both pieces of legislation are being marked up by the House Energy and Commerce Committee this week.
“In this era of divided government, the only way we can fully address the issues impacting the American people is to find a bipartisan solution that can be implemented into law,” said Rep. Tom O’Halleran, D-Ariz., the Blue Dog co-chair for policy.
“The rising cost of prescription drugs is forcing hardworking families to choose between life-saving medication and other necessities,” he continued. “Congress must act to bring those prices down and increase transparency surrounding drug pricing. Today, the Blue Dogs have come together to address this problem by supporting bipartisan legislation that does just that.”
The Payment Commission Act provides Congress’ independent advisory bodies, the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission, access to certain drug pricing data that will help them formulate recommendations on how to improve the Medicare and Medicaid programs and lower prescription drug prices.
The Act was introduced by O’Halleran and with Representatives Earl L. “Buddy” Carter, R-Ga., Tom Rice, R-S.C., and Jimmy Panetta D-Calif., who believe the legislation will lead to meaningful policy reforms that will ultimately help patients.
Meanwhile, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act, introduced by Blue Dog Co-Chair Representative Kurt Schrader, D-Ore., and Georgia’s Carter, aims to keep drug prices down by increasing competition in the generic drug market.
Currently, drug manufacturers are guaranteed 180 days of market exclusivity when they are the first to file a generic drug application with the FDA.
Intended to reward manufacturers for bringing new low-cost drugs to the market, the current legislative regime includes a flaw that effectively stymies competition.
The 180 days of market exclusivity begin once the first to file manufacturer starts marketing their drug, but even before the first to market begins marketing, all other generic competitors are blocked from coming to market.
This allows manufacturers to “park” the exclusivity before receiving final approval, blocking competition for more than the 180 days intended by the law, the Blue Dog Coalition said.
In these cases, no other generics can come to the market until the first manufacturer receives final approval, begins marketing the drug, and the subsequent 180 days have passed.
The BLOCKING Act would stop such first generic drug “parking” by mandating that if a second generic drug application is blocked from approval solely due to a first generic drug manufacturer parking their exclusivity at the tentative approval stage, the 180 days immediately begins to run, preventing limitless delays.
The legislation mirrors a proposal to “speed development of more affordable generics to spur competition” that was included in the Trump administration’s FY2019 budget proposal.
“Too many patients across this country feel a severe impact from rising drug prices, often on prescriptions they’ve been filling for years,” Representative Schrader said.
“I have long said there is not one silver bullet solution to this crisis, however, we do know that increasing competition on the drug market places a check on manufacturers and keeps costs down,” he continued. “My bill is one such solution that targets and eliminates unnecessary delays in allowing more drugs on the market, ensuring that manufacturers are still incentivized to produce more drugs and that markets continue to see robust competition.”
In The News
DALLAS — With opioid-related deaths on the rise each year in the U.S., Texas has become the first state to offer a life-saving overdose drug online, freeing users of the stigma associated with drug use. Last week, Texas began offering Naloxone, an opioid antagonist, for purchase... Read More
The Blue Dog Coalition has endorsed H.R. 2483, also known as the Fentanyl Sanctions Act, which aims to pressure the Chinese government to honor its commitment to make all forms of fentanyl illegal and provide the United States with more tools and resources to go after... Read More
This week, U.S. Representatives Brad Schneider, D-Ill., and Elise Stefanik, R-N.Y., announced the introduction of new bipartisan legislation to improve primary care options for individuals with high-deductible health insurance plans. H.R. 2774, the Primary Care Patient Protection Act of 2019, would create a primary care benefit... Read More
The health care debate has Democrats on Capitol Hill and the presidential campaign trail facing renewed pressure to make clear where they stand: Are they for “Medicare for All”? Or will they take up the push to protect the Affordable Care Act? Obamacare advocates have found... Read More
WASHINGTON — Most states are keeping a close eye on opioid overdose deaths, but they may need to start focusing on cocaine and other stimulants as well. It turns out that the same lethal drug that has been driving the nation’s spiraling opioid epidemic is also... Read More
For the first time in history, renewable energy surpassed coal earlier this month as a source of electricity generation in the United States, the Brookings Institution reported Wednesday. The paper underlying the report attributes this remarkable development to U.S. municipalities and businesses striving to fill the... Read More